Supriya Lifescience Limited (BOM:543434)
681.25
-3.65 (-0.53%)
At close: Feb 13, 2026
Supriya Lifescience Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 7,355 | 6,965 | 5,703 | 4,609 | 5,300 | 3,912 |
Revenue | 7,355 | 6,965 | 5,703 | 4,609 | 5,300 | 3,912 |
Revenue Growth (YoY) | 9.68% | 22.12% | 23.73% | -13.04% | 35.49% | 22.25% |
Cost of Revenue | 2,266 | 2,343 | 2,322 | 1,961 | 2,035 | 1,329 |
Gross Profit | 5,088 | 4,622 | 3,381 | 2,649 | 3,266 | 2,583 |
Selling, General & Admin | 982.71 | 859.5 | 724.21 | 730.21 | 655.81 | 501.41 |
Other Operating Expenses | 1,464 | 1,153 | 896.37 | 628.48 | 465.44 | 350.31 |
Operating Expenses | 2,707 | 2,217 | 1,779 | 1,477 | 1,222 | 919.33 |
Operating Income | 2,381 | 2,405 | 1,602 | 1,172 | 2,043 | 1,664 |
Interest Expense | -6.34 | -4.81 | -35.91 | -30.84 | -41.98 | -40.8 |
Interest & Investment Income | 40.19 | 40.19 | 83.57 | 95.16 | 70.94 | 49.91 |
Other Non Operating Income (Expenses) | -1.58 | -13.29 | -15.56 | -0.02 | 0.1 | 0.13 |
EBT Excluding Unusual Items | 2,414 | 2,427 | 1,635 | 1,236 | 2,072 | 1,673 |
Gain (Loss) on Sale of Investments | 55.65 | 55.65 | 22.4 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | -1.11 | - | - |
Pretax Income | 2,467 | 2,485 | 1,657 | 1,235 | 2,072 | 1,673 |
Income Tax Expense | 614.38 | 605.23 | 465.76 | 336.3 | 554.35 | 437.16 |
Net Income | 1,853 | 1,880 | 1,191 | 898.57 | 1,518 | 1,236 |
Net Income to Common | 1,853 | 1,880 | 1,191 | 898.57 | 1,518 | 1,236 |
Net Income Growth | 6.17% | 57.80% | 32.56% | -40.81% | 22.83% | 68.38% |
Shares Outstanding (Basic) | 80 | 80 | 80 | 80 | 80 | 73 |
Shares Outstanding (Diluted) | 80 | 80 | 80 | 80 | 80 | 73 |
Shares Change (YoY) | -0.20% | - | - | - | 9.97% | - |
EPS (Basic) | 23.04 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 |
EPS (Diluted) | 23.04 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 |
EPS Growth | 6.36% | 57.77% | 32.62% | -40.83% | 11.68% | 68.38% |
Free Cash Flow | - | 22.99 | -323.48 | -443.05 | -111.03 | 276.48 |
Free Cash Flow Per Share | - | 0.29 | -4.02 | -5.50 | -1.38 | 3.78 |
Dividend Per Share | - | 1.000 | 0.800 | 0.600 | 0.600 | 0.540 |
Dividend Growth | - | 25.00% | 33.33% | - | 11.11% | -73.00% |
Gross Margin | 69.19% | 66.36% | 59.28% | 57.46% | 61.61% | 66.03% |
Operating Margin | 32.38% | 34.53% | 28.10% | 25.42% | 38.55% | 42.53% |
Profit Margin | 25.19% | 26.99% | 20.89% | 19.49% | 28.64% | 31.59% |
Free Cash Flow Margin | - | 0.33% | -5.67% | -9.61% | -2.10% | 7.07% |
EBITDA | 2,612 | 2,601 | 1,752 | 1,281 | 2,136 | 1,724 |
EBITDA Margin | 35.52% | 37.34% | 30.72% | 27.80% | 40.31% | 44.06% |
D&A For EBITDA | 231.05 | 196.15 | 149.62 | 109.7 | 93.01 | 60 |
EBIT | 2,381 | 2,405 | 1,602 | 1,172 | 2,043 | 1,664 |
EBIT Margin | 32.38% | 34.53% | 28.10% | 25.42% | 38.55% | 42.53% |
Effective Tax Rate | 24.90% | 24.36% | 28.11% | 27.23% | 26.75% | 26.13% |
Revenue as Reported | 7,464 | 7,063 | 5,810 | 4,704 | 5,376 | 3,962 |
Advertising Expenses | - | 53.82 | 47.34 | 173.92 | 165.03 | 173.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.